Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 5/20 | 0.37 |
| ▸ | KDM5A | P29375 | 4/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399383 | 0.88 | KDM4E (0.60) | KDM4EHPGDKEAP1ALDH1A1RAB9A | |
| SCHEMBL2397310 | 0.83 | KDM4E (0.42) | KDM4EHPGDALDH1A1SMN1; SMN2KDM5A | |
| SCHEMBL4728675 | 0.82 | KDM5B (0.43) | KDM4EHPGDKEAP1ALDH1A1RAB9A | |
| SCHEMBL2394770 | 0.79 | ELANE (0.37) | KDM4EHPGDALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL29893950 | 0.76 | ALDH1A1 (0.47) | KDM4EHPGDKEAP1ALDH1A1RAB9A | |
| SCHEMBL7321877 | 0.75 | PARP1 (0.61) | KDM4EHPGDALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL8952892 | 0.74 | ALDH1A1 (0.47) | KDM4EHPGDKEAP1ALDH1A1RAB9A | |
| SCHEMBL7863162 | 0.74 | ALDH1A1 (0.47) | KDM4EHPGDKEAP1ALDH1A1RAB9A | |
| SCHEMBL18758064 | 0.74 | ALDH1A1 (0.47) | KDM4EHPGDKEAP1ALDH1A1RAB9A | |
| SCHEMBL4244593 | 0.73 | ALDH1A1 (0.46) | KDM4EHPGDKEAP1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542533-B1 | FLUORALKYL-SUBSTITUTED 2-AMIDOBENZIMIDAZOLES AND THEIR USE FOR INCREASING STRESS TOLERANCE IN PLANTS | BAYER IP GMBH (DE) | 2014-09-10 | — | — | EP | disclosed |
| EP-2561759-A1 | Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth | Bayer Cropscience AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2542533-A1 | FLUOROALKYL-SUBSTITUTED 2-AMIDOBENZIMIDAZOLES AND THE USE THEREOF FOR BOOSTING STRESS TOLERANCE IN PLANTS | Bayer Intellectual Property GmbH (DE) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011107504-A1 | FLUOROALKYL-SUBSTITUTED 2-AMIDOBENZIMIDAZOLES AND THE USE THEREOF FOR BOOSTING STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2011-09-09 | — | — | WO | disclosed |
| US-20110218103-A1 | Fluoroalkyl-substituted 2-amidobenzimidazoles | BAYER CROPSCIENCE AG (DE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218103-A1 | Fluoroalkyl-substituted 2-amidobenzimidazoles | BOLA2; BOLA2B, ARFIP2, PFAS | KDM4E 2009/4885HPGD 3714/4885KEAP1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.